Lipocine Inc. — Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2013. This is an annual report, not a standalone fourth-quarter report; quarterly results are not clearly provided in the filing. Lipocine is a pre-commercial specialty pharmaceutical company developing oral drug-delivery products, principally for men’s and women’s health. On July 24, 2013, it completed a reverse merger with Marathon Bar Corp.; the financial statements reflect Lipocine Operating as the accounting acquirer.
Financial performance and position
| Metric | FY 2013 / Dec. 31, 2013 | FY 2012 / Dec. 31, 2012 |
|---|---|---|
| Revenue | $0 | $7.71 million |
| Research and development expense | $5.12 million | $2.28 million |
| General and administrative expense | $3.64 million | $1.55 million |
| Net income (loss) | $(10.59) million | $3.89 million |
| Basic and diluted EPS | $(1.44) | $0.85 |
| Cash and cash equivalents | $45.26 million | $5.38 million |
| Cash used in operating activities | $8.59 million | $3.18 million |
| Total liabilities | $1.28 million | $0.25 million |
| Accumulated deficit | $47.86 million | $37.27 million |
No product-sale revenue was reported. Profit margins are not meaningful given the absence of revenue and the company’s development-stage operations. The balance sheet reports no borrowings; the company also disclosed no credit facility or committed sources of capital.
FY 2013 financing activities provided $48.48 million, primarily from a July private placement and November–December public offering. The company reported approximately $35.7 million and $12.5 million of net proceeds, respectively. It said existing resources were expected to cover projected operating requirements for 2014, while additional capital would be needed at some point to support longer-term development and commercialization.
Material changes versus 2012
- Revenue fell to zero from $7.71 million, principally because the Abbott license and collaboration agreement ended in March 2012 and the remaining $7.5 million of deferred revenue was recognized in 2012.
- Net income in 2012 became a substantial loss in 2013. The 2012 profit was primarily attributable to the deferred-revenue recognition; 2013 included no revenue, higher development and public-company costs, $1.01 million of reverse-merger costs, and a $0.91 million stock-related settlement expense.
- R&D expense increased by $2.84 million, mainly reflecting external clinical, manufacturing and research costs for LPCN 1021. G&A expense rose by $2.08 million, including greater professional fees and personnel costs associated with becoming a public company.
- Cash increased materially following equity financings, while operating cash use rose by $5.41 million. Common shares outstanding were 12,668,393 at year-end and 12,772,177 as of March 27, 2014.
Programs, outlook and key risks
- LPCN 1021: Oral testosterone replacement candidate in the pivotal Phase 3 SOAR study. Enrollment began in the first quarter of 2014; results were expected in the second half of 2015, subject to enrollment timing. The company anticipated an NDA filing in the second half of 2015 if the trial and required safety work were successful. It estimated approximately $20 million to complete the development process through the planned filing, while noting significant uncertainty around timing and cost.
- Phase 2 evidence: At 225 mg twice daily, the candidate met the reported primary and secondary endpoints on day 15. On day 29, it missed the lower-bound 95% confidence-interval criterion for a primary endpoint; the company attributed this possibly to the small sample of nine subjects. The short Phase 2 duration and results do not establish that Phase 3 will succeed.
- LPCN 1111: Earlier-stage oral testosterone candidate. A Phase 1 study in eight postmenopausal women was completed; a proof-of-concept study in hypogonadal men was planned for the first half of 2014.
- LPCN 1107: Early-stage oral candidate intended to prevent preterm birth. The company had filed an IND and reported enrolling women in a Phase 1/2 pharmacokinetic study in early 2014. Oral administration of hydroxyprogesterone caproate had not been established in pregnant women, and safety, absorption and regulatory requirements remained uncertain.
- Management expected significant ongoing losses and increasing expenses. The company had no product revenues and had never commercialized a drug; it stated that additional capital would ultimately be required and might not be available on acceptable terms.
- Important risks include clinical-trial failure or delay, regulatory review, manufacturing and supplier dependence, competition (including another company’s oral testosterone candidate), reimbursement and market acceptance, and the possibility that Lipocine would not be first to market. The FDA was investigating possible cardiovascular risks associated with testosterone products, a potential market and regulatory risk noted in the filing.
- Testosterone is a Schedule III controlled substance. Lipocine also disclosed dependence on contract research and manufacturing providers, including Encap as the sole supplier of LPCN 1021 capsules for the Phase 3 study, and reliance on two TU suppliers without supply agreements.
- A related-party transaction transferred cough-and-cold intellectual property and a development agreement to Spriaso, an entity majority-owned by company directors and affiliates. Lipocine may receive 20% of Spriaso’s net proceeds, capped at $10 million, and licensed the intellectual property back for fields outside cough and cold.
- The company reported two material weaknesses in financial reporting controls—insufficient accounting expertise and insufficient accrual-process controls—and concluded that internal controls and disclosure controls were not effective at December 31, 2013. Management reported corrective steps underway. KPMG issued an unqualified audit opinion on the financial statements.
- No material legal proceedings or off-balance-sheet arrangements were reported. The filing disclosed no current plans for future cash dividends.
Most important facts for investors to verify
- Progress, enrollment, endpoint results and safety findings from the LPCN 1021 Phase 3 trial, along with the status and cost of remaining studies and any NDA submission.
- Actual cash burn and financing needs relative to management’s stated ability to fund 2014 operations; review subsequent financing, dilution and share-count changes.
- Whether the reported material weaknesses have been remediated and whether later filings report effective controls or further accounting issues.
- Manufacturing scale-up, cGMP readiness, supply availability and any commercial supply arrangements for LPCN 1021.
- Regulatory developments and competitive timing in testosterone replacement, including cardiovascular safety scrutiny, reimbursement prospects and the status of competing oral candidates.
- Terms, governance and realized proceeds, if any, from the related-party Spriaso arrangements, and any royalties owed to Abbott if prior formulations or data are used.